Old Web
English
Sign In
Acemap
>
authorDetail
>
Zhihong Yang
Zhihong Yang
Bristol-Myers Squibb
Internal medicine
Medicine
Oncology
CAR T-cell therapy
Refractory Multiple Myeloma
2
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
2021
Blood
Noopur Raje
Jesus G. Berdeja
Paula Rodriguez-Otero
Damian J. Green
Sundar Jagannath
Sagar Lonial
Adrianna Gipson
Andrea Caia
Nathan Martin
Zhihong Yang
Gianfranco Pittari
Maria-Victoria Mateos
Show All
Source
Cite
Save
Citations (0)
Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
2020
Blood
Yi Lin
Noopur Raje
Jesus G. Berdeja
David S. Siegel
Sundar Jagannath
Deepu Madduri
Michaela Liedtke
Jacalyn Rosenblatt
Marcela V. Maus
Monica Massaro
Fabio Petrocca
Andrea Caia
Zhihong Yang
Timothy B. Campbell
Kristen Hege
Nikhil C. Munshi
James N. Kochenderfer
Show All
Source
Cite
Save
Citations (25)
1